Influence of enalapril or losartan therapy on insulin resistance in patients with essential hypertension;Wplyw leczenia enalaprylem lub losartanem na stopien insulinoopornosci u chorych na samoistne nadcisnienie tetnicze

Polskie Archiwum Medycyny Wewnetrznej

Volumn 103, Issue 3-4, 2000, Pages 123-131

  Akel, Ali ^a   Wieçcek, Andrzej ^a   Nowicki, Michał ^a   Kokot, Franciszek ^a  

^a Klinika I Katedra Nefrologii   (Poland)

Author keywords

Arterial hypertension; Hyperinsulinaemia; Insulin resistance; Renin angiotensin system

Indexed keywords

ENALAPRIL; LOSARTAN; DIAGNOSTIC AGENT; INSULIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; ESSENTIAL HYPERTENSION; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; ADULT; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HYPERTENSION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; BLOOD GLUCOSE; ENALAPRIL; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; LOSARTAN; MALE; MIDDLE AGED;

EID: 0033652277     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kokot F., Kokot T.: Samoistne nadciśnienie tȩtnicze (SNT) w 1995. Post. Nauk. Med., 1996, 9, 138.
2. Wiȩcek A.: Rola układu renina-angiotensyna w patogenezie nadciśnienia tȩtniczego. Medipress, 1999, (suppl.) 4, 7.
3. Dangel D.R., Mayuga R.S., Kairis G.M., Goldberg A.P., Weir M.R.: Effect of dietary sodium on insulin sensitivity in older, obese, sedentary hypertensives. Am. J. Hypertens., 1997, 10, 964.
4. O'Shaughnessy I.M., Myers T.J., Stepniakowski K. i wsp.: Glucose metabolism in abdominally obese hypertensive and normotensive subjects. Hypertension, 1995, 26, 186.
5. Roney D.P., Neely R.D.G., Ennis C.N. i wsp.: Insulin action and hepatic glucose cycling in essential hypertension. Metabolism, 1992, 41, 317.
6. Facchini F., Chen Y-.D.I., Cklinkingbeard C., Jeppesen J., Reawen G.M.: Insulin resistance, hyperinsulinemia and dyslipidemia in nonobese individuals with a family history of hypertension. Am. J. Hypertens., 1992, 5, 694.
7. Lembo G., Capaldo B., Rendina V.: Acute noradrenergic activation induces insulin resistance in human skeletal muscle. Am. J. Physiol., 1994, 266, 242.
8. Johnston C.: Biochemistry and pharmacology of the renin-angiotensin system. Drugs, 1990, 39, (suppl. 1), 21.
9. Swales I., Samani N.: Vascular RAA system. J. Hum. Hypertens., 1993, 7, (suppl. 2), 53.
10. Fogari R., Zoppi A., Lazzari P.: Effects of perindopril and losartan on fibrinogen and insulin sensitivity in overweight hypertensive patients. Eur. Heart J., 1997, 18, 535.
11. Fogari R., Zoppi A., Lazzari P., Preti P., Mugellini A., Corradi L.: ACE - inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J. Cardiovasc. Pharmacol., 1998, 32:616.
12. Valensi P., Derobert E., Genthon R., Riou J.P.: Effects of ramipril on insulin sensitivity in obese patients. Time course study of glucose infusion rate during euglycaemic hyperinsulinaemic clamp. Diabetes Metab., 1996, 22, 197.
13. Santoro D., Natali A., Palombo C. i wsp.: Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension, 1992, 20, 181.
14. Spustova V., Stefikova K., Oksa A., Dzurik R.: A protein-restricted diet combined with ACE inhibitors does not improve insulin sensitivity in renal hypertension. VnitrLek., 1996, 42, 157.
15. 1. Probl. Ter. Monit. 1997, 1, 9.
16. Brunner H.R.: The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am. J. Hypertens., 1997, 10, 311.
17. Januszewicz A.: Losartan, pienvszy antagonista receptorów angiotensyny II, w świetle wyników badań klinicznych. Probl. Ter. Monit., 1997, 1, 46.
18. 1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol. Ther., 1997, 74, 181.
19. Moan A., Høieggen A., Nordby G., Eide I.K., Kjeldsen S.E.: Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity? J. Hum. Hypertens., 1995, 9, (suppl. 5), 45.
20. Kokot F., Stupnicki R.: Metody radioimmunologiczne i radiokompetycyjne stosowane w klinice. PZWL, Warszawa, 1985.
21. Kokot F.: Metody badań laboratoryjnych stosowane w klinice. PZWL, Warszawa, 1969.
22. Istfan N.W., Plaisted C.S., Bistrian B.R., Blackburn G.L.: Insulin resistance versus insulin secretion in the hypertension of obesity. Hypertension, 1992, 19, 385.
23. Ferrannini E., Buzzigoli G., Bonadonna R., i wsp.: Insulin resistance in essential hypertension. N. Engl. J. Med., 1987, 317, 350.
24. Ferrannini E., Taddei S., Santoro D. i wsp.: Independent stimulation of glucose metabolism and Na/K exchange by insulin in the human forearm. Aw. J. Physiol., 1988, 255, 953.
25. De Fronzo R.A., Tobin I.D., Andres R.: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol., 1979, 237, 214.
26. Nowicki M.: Rola insuliny w regulacji gospodarki wapniowo-fosforanowej u chorych na samoistne nadciśnienie tȩtnicze i chorych z przewlekła̧ niewydolnościa̧, nerek. Rozprawa habilitacyjna. ŚLAM, Katowice, 1997.
27. Lind L., Berne C., Lithell H.: Prevalence of insulin resistance in essential hypertension. J. Hypertens., 1995, 13, 1457.
28. Modem M., Halkin H., Almog S. i wsp.: Hyperinsulinemia. A link beetween hypertension, obesity and glucose intolerance. J. Clin. Invest., 1985, 75, 809.
29. Mak R.H.K., De Fronzo R.A.: Glucose and insulin metabolism in uremia. Nephron, 1992, 61, 377.
30. Kissebach A.H., Vydelingum N., Murray R. i wsp.: Relation of body fat distribution to metabolic complications of obesity. J. Clin. Endocrinol. Metab., 1982, 54, 254.
31. Peirs A.N., Mueller R.A., Smith G.A., Struve M.F., Kissebah A.H.: Splanchnic insulin metabolism in obesity: influence of body fat distribution. J. Clin. Invest., 1986, 78, 1648.
32. Laakso M., Karjalainen L., Lempiäinen-Kitosa P.: Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension, 1996, 28, 392.
33. Paolisso G., Tagliamonte M.R., Gambardella A. i wsp.: Losartan mediated improvement in insulin action is mainly due to an increase in nonoxidative glucose metabolism in blood in insulin-resistant hypertensive patients. J. Hum. Hypertens., 1997, 11, 307.
34. 1 receptors. Eur. J. Pharmacol., 1995, 282, 77.
35. Tomiyama H., Kushirp T., Abeta H. i wsp.: Kinins contribute to the improvement of insulin sensitivity during treatment with angiotenstn converting enzyme inibitor. Hypertension, 1994, 23, 450.
36. Henriksen E.J., Jacob S., Augusti: Glucose transport activity in insulin-resistant rat muscle. Effects of angiotensin-converting enzyme inhibitors and bradykinin antagonism. Diabetes, 1996, (suppl. 1), 125.
37. Pollare T., Lithell H., Morlin C., Prantare H., Hvarfner A.: Metabolic effects of diltiazem and atenolol: results from a randomized, double blind study with parallel groups. J. Hypertens., 1989, 7, 551.
38. Pollare T., Lithell H., Selinus I., Berne C.: Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Brit. Med. J., 1989, 298, 1152.
39. Hornig B., Kohler C., Drexler H.: Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation, 1997, 95, 1115.
40. Gainer J.V., Morrow J.D., Loveland A., King D.J., Brown N.J.: Effects of bradykinin-receptor blockade on the response to angiotensin converting-enzyme inhibitor in normotensive and hypertensive subjects. N. Engl. J. Med., 1998, 339, 1285.